Floatz logo

immunoglobulin G4-kappa, anti-[Homo sapiens LILRB2 (leukocyte immunoglobulin like receptor B2, ILT4, LIR-2, MIR10, CD85d)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-450) [VH humanized (Homo sapiens IGHV2-5*01 (86,9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [10.7.15] (26-35.53-59.98-112)) (1-123)- Homo sapiens IGHG4*01, IGHG4v5 h P10, nG4m(a) CH2 L92 (CH1 (124-221), hinge 1-12 S10>P (231) (222-233), CH2 L92 (312) (234-343), CH3 (344-448), CHS (449-450)) (124- 450)], (137-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA Homo sapiens IGKV1-33*01 (83.2%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50- 52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232- 232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Cancer

Jounce Therapeutics, Inc.monoclonal_antibodyPhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

1412 Active assets in the Cancer cohort.

View all 50

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →